Allurion Technologies shares soared 200% Friday as it planned to test its gastric balloon with the key ingredient in popular weight-loss drugs to see if the combination improves patients' muscle mass.

tripled Friday as the maker of the Allurion Gastric Balloon weight-loss device looked to take advantage of the booming obesity drug market. The company announced it would begin a study to see if ...

Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.

Allurion (NYSE: ALUR) surged 83% premarket after revealing a clinical study combining its gastric balloon product with GLP-1 drugs, showing muscle mass maintenance. Stardust Power (NASDAQ ...

and manage weight-loss therapy for patients regardless of their treatment plan. The Allurion Gastric Balloon is an investigational device in the United States. For more information about Allurion ...

It seeks to establish this mix as a standard for treatment of obesity. Along with a Virtual Care Suite that provide tools for healthcare professionals to monitor and modify treatments, the Allurion ...

The shocking truth about a Chinese spy balloon that entered US airspace last year has finally been revealed. Panic swept the nation when officials spotted a massive, white balloon float over the ...